ClinicalTrials.gg
CompletedNCT00806546NP101-009Updated Feb 4, 2016Results posted

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

A Phase 3 interventional study of NP101 in Migraine Disorders, sponsored by NuPathe Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by NuPathe Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Teva Pharmaceutical Industries, Ltd..

Enrollment
6th of 19
514 · median 353
Started
2009
with 3 others
Phase 3
12 of 20
none open now
Registered
7th of 20
by date

Among the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd., this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2009, is one of 12 in phase 3, and was the 7th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Migraine Disorders, anywhere →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an adult male or female, age range 18 years to 65 years.
  • Subject has a diagnosis of migraine headache, with or without aura, as defined in the ICHD-II and the diagnosis was made before the age of 50.
  • Subject experiences mild to severe headaches during a migraine attack based on subject testimony.
  • Subject has at least a one year history of migraine based upon subject testimony.
  • Subject typically experiences at least two migraine headaches per month based on subject testimony.
  • Subject will be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, and laboratory profile. Subjects will not have any abnormal laboratory parameters, vital signs or ECG parameters in order to qualify for enrollment.
  • Female subject of (not surgically sterile or 2 years ) must have a negative pregnancy test at screening and prior to enrollment.
  • Subject must have a negative drug screen.
  • Subject must be capable of reading and understanding either English or Spanish subject information materials. Be able to successfully apply a practice patch, carry-out all subject procedures, and be able to voluntarily sign and date an IC agreement approved by an IRB.
  • Subject has at least two acceptable patch application sites (upper arms or upper thighs) that are relatively hair free and has no scars, tattoos, scratches or bruises.
  • In the investigator's opinion the subject is on a stable medication regimen.

Exclusion criteria

Exclusion Criteria:

  • Subject has more than 15 headache days per month for any of the three months prior to screening.
  • Subject has suspected or confirmed cardiovascular disease that contraindicates study participation.
  • Subject has a history of epilepsy or condition associated with a lowered seizure threshold.
  • Subject has Raynaud's disease.
  • Subject has a history of basilar or hemiplegic migraines.
  • Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or dependence.
  • Subject has taken non-triptan serotonergic drugs including SSRIs (including Wellbutrin), SNRIs, TCAs, MAOIs or preparations containing St. John's Wort within 1 month prior to screening and/or is planning to start any of these medications during the study.
  • Subject is unwilling to discontinue use of a PD5 inhibitor (e.g. Viagra®, Levitra®, or Cialis®) through the Final Visit.
  • Subject has a history of a significant allergy or to any component of the study patch used in this study.
  • Subject has any generalized skin irritation or disease including eczema, psoriasis, melanoma, or contact dermatitis that would affect transdermal absorption of sumatriptan and / or affect the subjects ability to assess skin irritation.
  • Subject has abnormal laboratory parameters, vital signs or parameters.
  • Subject is known to be , or positive.
  • Subject has a diagnosis of bipolar disorder or current major depressive disorder, or has any other medical or psychiatric condition, that in the investigator's opinion would make the subject unsuitable for enrollment / participation in the study.
  • Subject has hepatic dysfunction defined as /AST or SGPT/ALT ≥ 2 times the (ULN) range, or alkaline phosphatase or total ≥ 1.5 times the ULN range or if in the opinion of the Investigator the subject's history, physical examination or other laboratory tests suggest hepatic dysfunction.
  • Female subject who is pregnant, breast feeding, or if of , is not using or is unwilling to use an effective form of during the study and for a period of 30 days following dosing.
  • Subject has known history of failure to respond to sumatriptan (ineffective or poorly tolerated).
  • Subject has participated in a clinical study within 30 days of screening or is planning to participate in another clinical study.
  • Subject has been previously enrolled in NP101-008.
  • Subject is electrically sensitive (e.g., prior iontophoresis with adverse outcome related to the current delivered by the device) or who have electrically sensitive support systems (e.g., pacemaker) or other medical condition that in the investigator's opinion would make the subject unsuitable for enrollment in the study.
  • Subject who is considered by investigator or NuPathe, for any reason, to be an unsuitable candidate for this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    NP101

    sumatriptan iontophoretic transdermal patch

    Drug: NP101

Interventions

06

What researchers measure

Primary outcomes

  1. Subject Self-examination of Skin Irritation

    For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).

    Time frame: 24 hours post patch application

07

Results

Posted Mar 20, 2013

Participant flow

The study was initiated March 2009 and completed in May 2011. Patients were enrolled from 34 investigative sites across the United States.

Participant flow — Overall Study
MilestoneNP101
Started514
Completed207
Not completed307
Withdrew: Enrolled, not treated35
Withdrew: Lost to follow-up32
Withdrew: Adverse event74
Withdrew: Withdrawal by subject75
Withdrew: Protocol violation49
Withdrew: Various42

Outcome measures

PrimarySubject Self-examination of Skin Irritation

For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).

Time frame:
24 hours post patch application
Reported as:
Mean · scores on a scale
Subject Self-examination of Skin Irritation
scores on a scaleNP101
Subject Self-examination of Skin Irritation0.6 ± 0.86

Adverse events

Collected over All adverse events were collected from Screening until 30 days after the last study visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NP101—9/479 (1.9%)177/479 (37%)
Most frequent serious events
Most frequent serious events
EventNP101
Atrial fibrillationCardiac disorders1/479
Supraventricular tachycardiaCardiac disorders1/479
GoiterEndocrine disorders1/479
Bile duct stoneHepatobiliary disorders1/479
CholelithiasisHepatobiliary disorders1/479
Back painMusculoskeletal and connective tissue disorders1/479
HeadacheNervous system disorders1/479
SyncopeNervous system disorders1/479
Ruptured ectopic pregnancyPregnancy, puerperium and perinatal conditions1/479
Most frequent other events
Most frequent other events
EventNP101
Application site painGeneral disorders93/479
Application site pruritusGeneral disorders67/479
Application site reactionGeneral disorders29/479
Application site discolorationGeneral disorders28/479
Application site drynessGeneral disorders27/479
Application site paraesthesiaGeneral disorders26/479

Baseline characteristics

Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months. The safety population included all subjects who applied at least one NP101 patch. Of the 514 subjects enrolled, 35 subjects did not treat for a total of 479 subjects in the safety population.

Age, Categorical
Age, Categorical(Participants)NP101
<=18 years0
Between 18 and 65 years479
>=65 years0
Age, Continuous
Age, Continuous(years)NP101
Mean41.7 ± 11.85
Sex: Female, Male
Sex: Female, Male(Participants)NP101
Female392
Male87
Region of Enrollment
Region of Enrollment(participants)NP101
United States479
08

Study locations

31 sites
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Irvine, California, United States
  • Newport Beach, California, United States
  • San Francisco, California, United States
  • Santa Monica, California, United States
  • Walnut Creek, California, United States
  • Fairfield, Connecticut, United States
  • Hallandale Beach, Florida, United States
  • Ocala, Florida, United States
  • Sunrise, Florida, United States
  • Atlanta, Georgia, United States
  • Decatur, Georgia, United States
  • Savannah, Georgia, United States
  • Crestview Hills, Kentucky, United States
  • Ann Arbor, Michigan, United States
  • St. Louis, Missouri, United States
  • Mount Vernon, New York, United States
  • Plainview, New York, United States
  • Greensboro, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Clarksville, Tennessee, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Alexandria, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 10 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2008
First posted
Dec 11, 2008
Start
Feb 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Results delay requested
Nov 7, 2012
Results first posted
Mar 20, 2013
Last update
Feb 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00806546
Lead sponsor
NuPathe Inc.
Responsible party
Sponsor
First posted
Dec 11, 2008
Start date
Feb 2009
Primary completion
May 2011
Completion
May 2011
Results posted
Mar 20, 2013
Last update
Feb 4, 2016

Study contacts

Mark Pierce, M.D., PhD.
study director · NuPathe Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement · Sumatriptan

Start the discussion